Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer Patients
John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
Zalcberg says average survival is usually between 12 and 14 months, although a randomized phase II study of regorafenib in AOGC patients has shown improved progression-free survival. Zalcberg and his team of medical professionals examined Caucasian patients from Australia, New Zealand, and Canada compared to patients from Korea.
Zalcberg says he hopes to enter a phase III trial study to prove the benefits of regorafenib in the near future.
